Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Tocilizumab Venkiteshwaran AMAbs 2009[Sep]; 1 (5): 432-8Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and several types of arthritis. The product is approved in the European Union for treatment of moderate-to-severe rheumatoid arthritis, and is currently undergoing review by the US Food and Drug Administration for this condition. Tocilizumab has also been studied for potential use in the treatment of other IL-6 related disorders including Crohn disease.|*Antibodies, Monoclonal/administration & dosage/adverse effects/immunology/therapeutic use[MESH]|Animals[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Arthritis, Rheumatoid/*drug therapy[MESH]|Castleman Disease/*drug therapy[MESH]|Clinical Trials as Topic[MESH]|Crohn Disease/*drug therapy[MESH]|Drug Administration Schedule[MESH]|European Union[MESH]|Humans[MESH]|Japan[MESH]|Mice[MESH]|Receptors, Interleukin-6/*immunology[MESH]|Treatment Outcome[MESH]|United States[MESH] |